ArticleCancer cell2008
The ever-lengthening arm of p53.
Article in Cancer cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.The Journal of biological chemistry · 2011Article
- Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.Nature reviews. Drug discovery · 2009Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
p53 is a pivotal bulwark against cancer, but exactly how it suppresses tumors remains elusive, in part because it modulates such diverse biological processes via so many downstream pathways. In a recent issue of Cell, Godar et al. (2008) now identify another string to p53's anticancer bow-repression of the CD44 cell-surface glycoproteins that coordinate many attributes of tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.